Sonus Pharmaceuticals to Release First Quarter Financial Results and Hold Conference Call on May 9
03 Mayo 2007 - 6:04PM
Business Wire
Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced that it
will release first quarter financial results on Wednesday, May 9,
at the close of market and hold a conference call at 1:30 P.M.
PT/4:30 P.M. ET. The first quarter conference call will be
broadcast live and can be accessed on the Sonus web site at
www.sonuspharma.com/events.html. The call will be archived at the
same link. A telephone replay of the call will be available from
May 9, 4:30 P.M. PT/7:30 P.M. ET, for one week at 800-405-2236 or
303-590-3000 for international calls; Conference ID: 11088543.
About Sonus Pharmaceuticals, Inc. Located near Seattle, Washington,
Sonus Pharmaceuticals is focused on the development of cancer drugs
that are designed to provide better efficacy, safety and
tolerability, and are more convenient to use. The Company�s lead
product candidate, TOCOSOL� Paclitaxel, is currently in a Phase 3
pivotal trial for the potential treatment of metastatic breast
cancer. TOCOSOL Paclitaxel is a vitamin E-based emulsion
formulation of paclitaxel that may have the ability to reduce
treatment-limiting side effects and improve anti-tumor activity.
Compared to currently marketed taxane products, TOCOSOL Paclitaxel
allows for shorter infusion times and does not require any
time-consuming preparation prior to administration. In addition to
the continuing development of TOCOSOL Paclitaxel, Sonus initiated a
Phase 1 clinical study for its second cancer drug, TOCOSOL
Camptothecin, in September 2006. For additional information on
Sonus, including past news releases, please visit
www.sonuspharma.com. Safe Harbor Certain statements made in this
press release are forward-looking such as those, among others,
relating to the development, safety and efficacy of therapeutic
drugs and potential applications for these products. As discussed
in Sonus Pharmaceuticals� filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for 2006,
actual results could differ materially from those projected in the
forward-looking statements as a result of the following factors,
among others:�the Company�s products will require extensive
clinical testing and approval by regulatory authorities; such
approvals are lengthy and expensive and may never occur; risks that
the Company will not be able to complete the Phase 3 clinical trial
for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL
Paclitaxel will be delayed or will not be successful; risks that
the FDA may not approve the TOCOSOL Paclitaxel New Drug
Application; risks that the Phase 1 clinical trial for TOCOSOL
Camptothecin will not be successful; risks of successful
development of therapeutic drugs; and risks that the Company may
not be successful in obtaining funding from third parties or
completing a financing necessary to support the costs and expenses
of clinical studies as well as research and development activities.
The Company undertakes no obligation to update the forward-looking
statements contained herein or to reflect events or circumstances
occurring after the date hereof.
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sonus Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Sonus Pharmaceuticals, Inc. Artículos de Noticias